Inotiv/$NOTV
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Inotiv
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Ticker
$NOTV
Sector
Primary listing
Industry
Life Sciences Tools & Services
Headquarters
Employees
2,026
ISIN
US45783Q1004
Website
Inotiv Metrics
BasicAdvanced
$63M
-
-$3.10
4.06
-
Price and volume
Market cap
$63M
Beta
4.06
52-week high
$6.20
52-week low
$1.15
Average daily volume
747K
Financial strength
Current ratio
1.505
Quick ratio
0.8
Long term debt to equity
274.344
Total debt to equity
284.576
Interest coverage (TTM)
-0.56%
Profitability
EBITDA (TTM)
27.507
Gross margin (TTM)
21.87%
Net profit margin (TTM)
-18.21%
Operating margin (TTM)
-4.25%
Effective tax rate (TTM)
14.89%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
-1.61%
Return on equity (TTM)
-47.95%
Valuation
Price to revenue (TTM)
0.108
Price to book
0.4
Price to tangible book (TTM)
-0.33
Price to free cash flow (TTM)
-0.961
Free cash flow yield (TTM)
-104.08%
Free cash flow per share (TTM)
-191.51%
Growth
Revenue change (TTM)
-13.09%
Earnings per share change (TTM)
11.49%
3-year revenue growth (CAGR)
20.07%
10-year revenue growth (CAGR)
34.93%
3-year earnings per share growth (CAGR)
-11.31%
10-year earnings per share growth (CAGR)
66.66%
What the Analysts think about Inotiv
Analyst ratings (Buy, Hold, Sell) for Inotiv stock.
Inotiv Financial Performance
Revenues and expenses
Inotiv Earnings Performance
Company profitability
Inotiv News
AllArticlesVideos
Inotiv, Inc. to Present at Jefferies Global Healthcare Conference 2025
GlobeNewsWire·1 month ago
Inotiv Reports Second Quarter Financial Results for Fiscal 2025 and Provides Business Update
GlobeNewsWire·2 months ago
Inotiv, Inc. to Report Fiscal 2025 Second Quarter Financial Results and Host Conference Call on Wednesday, May 7, 2025
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Inotiv stock?
Inotiv (NOTV) has a market cap of $63M as of June 27, 2025.
What is the P/E ratio for Inotiv stock?
The price to earnings (P/E) ratio for Inotiv (NOTV) stock is 0 as of June 27, 2025.
Does Inotiv stock pay dividends?
No, Inotiv (NOTV) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Inotiv dividend payment date?
Inotiv (NOTV) stock does not pay dividends to its shareholders.
What is the beta indicator for Inotiv?
Inotiv (NOTV) has a beta rating of 4.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.